SBIR/STTR Research Award

Fibronectin matrix mimetic, Chimectin as a first-in-class therapeutic for chronic wound healing

Award identifier 06cffd744e61edcd17b30c494d63016922b938fc9ab1d55f93537a1ec085b716Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$388,193

Program and phase

SBIR · Phase I

Award year

2024

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
EDI THERAPEUTICS LLC
Proposal award date
2024-05-01
Contract end date
2025-04-30
UEI
P6VEXK48QFJ8
Solicitation number
PA23-230
Topic code
200

Research abstract

ABSTRACT Chronic wounds have become a `silent epidemic' with health complications ranging from serious infections to limb amputations to death. In the U.S. alone, annual health care costs for treating chronic wounds are conservatively estimated at $32 billion. Treatment approaches for chronic wounds include surgical debridement, moist dressings, engineered skin substitutes, compression therapy, negative pressure therapy, skin grafts, and recombinant growth factors. Yet, none of these approaches has proven to be an efficient and effective therapy. Tissue repair occurs through a series of events mediated through interactions between various cell types and extracellular matrix (ECM) proteins. Fibronectin fibrils are a principal component of the wound ECM and play a key role in tissue formation. The Hocking lab has developed a series of soluble, recombinant fragments of fibronectin, termed “fibronectin matrix mimetics”, that “mimic” the structural and functional properties of insoluble fibronectin fibrils. Fibronectin matrix mimetics promote cell adhesion, proliferation, migration and contractility, modulate extracellular matrix composition, and induce local vasodilation - all of which contribute to effective tissue regeneration. Topical application of fibronectin matrix mimetics to full-thickness dermal wounds in diabetic mice accelerates epithelial maturation, and promotes granulation tissue deposition, remodeling, and re-vascularization. Thus, a primary target of the fibronectin matrix mimetics is chronic diabetic wounds. The goals of this project are to (i) fully characterize tissue responses to one of the fibronectin matrix mimetics, FNIII1H,8,10 (“Chimectin”) in genetically diabetic male and female mice, and (ii) test Chimectin's efficacy in a diabetic porcine dermal wound model. Results from these studies will lay the groundwork to advance Chimectin to clinical trials to test its ability to stimulate wound healing in diabetic patients.

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.